Bausch Health Company Insiders
BHC Stock | USD 8.53 0.08 0.95% |
Bausch Health's insiders are aggressively selling. The analysis of insiders' sentiment of trading Bausch Health Companies stock suggests that all insiders are panicking at this time. Bausch Health employs about 20.3 K people. The company is managed by 38 executives with a total tenure of roughly 171 years, averaging almost 4.0 years of service per executive, having 533.42 employees per reported executive.
William Humphries Chairman Executive Vice President Company Group Chairman, Dermatology |
Joseph Papa Chairman Chairman of the Board, Chief Executive Officer |
Bausch Health's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2023-12-05 | Seana Carson | Disposed 220 @ 7.38 | View | ||
2023-11-06 | Seana Carson | Disposed 43 @ 7.61 | View | ||
2023-09-06 | Seana Carson | Disposed 6685 @ 8.28 | View |
Monitoring Bausch Health's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Bausch |
Bausch Health's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bausch Health's future performance. Based on our forecasts, it is anticipated that Bausch will maintain a workforce of about 20270 employees by May 2024.Bausch Health's latest congressional trading
Congressional trading in companies like Bausch Health Companies, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Bausch Health by those in governmental positions are based on the same information available to the general public.
2020-08-27 | Representative Susie Lee | Disposed Under $15K | Verify |
Bausch Health Management Team Effectiveness
The company has Return on Asset of 0.0382 % which means that on every $100 spent on assets, it made $0.0382 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (6.8652) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.61, whereas Return On Tangible Assets are projected to grow to (0.06). At present, Bausch Health's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 2.7 B, whereas Total Assets are forecasted to decline to about 14.9 B.As of April 23, 2024, Common Stock Shares Outstanding is expected to decline to about 246.3 M. In addition to that, Net Loss is expected to decline to about (212.6 M)
Bausch Health Workforce Comparison
Bausch Health Companies is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 27,590. Bausch Health totals roughly 20,270 in number of employees claiming about 73% of equities under Health Care industry.
Bausch Health Profit Margins
The company has Net Profit Margin of (0.07) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of 0.21 %, which entails that for every 100 dollars of revenue, it generated $0.21 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.81 | 0.7078 |
|
|
Bausch Health Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bausch Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bausch Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bausch Health insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.2308 | 3 | 13 | 705,990 | 150,726 |
2023-12-01 | 1.0 | 4 | 4 | 16,676 | 2,288 |
2023-09-01 | 0.8 | 4 | 5 | 16,269 | 120,063 |
2023-06-01 | 13.0 | 13 | 1 | 279,562 | 1,929 |
2023-03-01 | 0.5714 | 12 | 21 | 1,033,324 | 59,123 |
2022-12-01 | 3.0 | 6 | 2 | 30,883 | 2,025 |
2022-09-01 | 11.0 | 11 | 1 | 734,670 | 15,389 |
2022-06-01 | 1.7647 | 30 | 17 | 929,265 | 763,516 |
2022-03-01 | 0.5227 | 23 | 44 | 1,460,990 | 558,448 |
2021-12-01 | 4.5 | 9 | 2 | 67,447 | 3,744 |
2021-09-01 | 3.0 | 12 | 4 | 238,491 | 14,854 |
2021-06-01 | 2.0 | 22 | 11 | 374,876 | 317,105 |
2021-03-01 | 1.619 | 34 | 21 | 1,377,114 | 807,889 |
2020-12-01 | 1.0 | 7 | 7 | 42,000 | 76,832 |
2020-09-01 | 0.8333 | 5 | 6 | 35,127 | 21,892 |
2020-06-01 | 3.375 | 27 | 8 | 6,064,443 | 1,172,387 |
2020-03-01 | 1.1667 | 35 | 30 | 1,320,046 | 254,338 |
2019-12-01 | 4.0 | 4 | 1 | 4,281 | 3,337 |
2019-09-01 | 1.0 | 8 | 8 | 118,516 | 65,682 |
2019-06-01 | 2.0 | 14 | 7 | 111,408 | 129,154 |
2019-03-01 | 1.6923 | 22 | 13 | 944,388 | 62,273 |
2018-12-01 | 2.3333 | 7 | 3 | 63,817 | 19,946 |
2018-09-01 | 0.5294 | 9 | 17 | 209,965 | 234,592 |
2018-06-01 | 6.0 | 24 | 4 | 283,978 | 105,400 |
2018-03-01 | 3.8333 | 23 | 6 | 8,656,748 | 7,089,655 |
2017-12-01 | 6.0 | 6 | 1 | 360,349 | 344,216 |
2017-09-01 | 1.5 | 6 | 4 | 18,836 | 1,003,273 |
2017-06-01 | 2.3333 | 14 | 6 | 254,703 | 20,408 |
2017-03-01 | 20.0 | 20 | 1 | 645,182 | 0.00 |
2016-12-01 | 0.8333 | 5 | 6 | 9,130,508 | 3,524,643 |
2016-09-01 | 1.1667 | 7 | 6 | 183,948 | 24,582 |
2016-06-01 | 2.4 | 24 | 10 | 12,778,244 | 18,240,000 |
2016-03-01 | 0.1429 | 1 | 7 | 1,096 | 57,408 |
2015-12-01 | 1.5 | 9 | 6 | 14,227 | 1,314,057 |
2015-06-01 | 1.0357 | 29 | 28 | 424,183 | 4,843,370 |
2015-03-01 | 0.9167 | 11 | 12 | 712,680 | 310,412 |
2014-12-01 | 1.3636 | 15 | 11 | 681,876 | 141,674 |
2014-09-01 | 1.0 | 4 | 4 | 18,810 | 30,119 |
Bausch Health Notable Stakeholders
A Bausch Health stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bausch Health often face trade-offs trying to please all of them. Bausch Health's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bausch Health's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
William Humphries | Executive Vice President Company Group Chairman, Dermatology | Profile | |
Joseph Papa | Chairman of the Board, Chief Executive Officer | Profile | |
Thomas Appio | Executive Vice President Company Group Chairman, International | Profile | |
Paul Herendeen | Chief Financial Officer, Executive Vice President | Profile | |
Joseph Gordon | President and Co-Head Bausch + Lomb/International | Profile | |
Christina Ackermann | Executive Vice President, General Counsel and Head of Commercial Operations | Profile | |
Mark McKenna | President - Salix Pharmaceuticals | Profile | |
Mirza Dautbegovic | Senior COO | Profile | |
Sarah Kavanagh | Independent Director | Profile | |
Richard DeSchutter | Independent Director | Profile | |
Robert Hale | Independent Director | Profile | |
Richard Schutter | Independent Director | Profile | |
Amy Wechsler | Independent Director | Profile | |
Robert Power | Independent Director | Profile | |
Argeris Karabelas | Independent Director | Profile | |
Thomas Ross | Lead Independent Director | Profile | |
Andrew Eschenbach | Independent Director | Profile | |
Elif McDonald | Director, Investor Relations | Profile | |
John Paulson | Independent Director | Profile | |
Russel Robertson | Independent Director | Profile | |
John Barresi | Controller, VP | Profile | |
D Hale | Independent Director | Profile | |
Jeff Hartness | Commercial Access | Profile | |
Arthur Shannon | IR Contact Officer | Profile | |
Tage MD | Chief RD | Profile | |
Robert Butz | VP Affairs | Profile | |
Brett Icahn | Independent Director | Profile | |
Seana Carson | Executive Counsel | Profile | |
Josh Coyle | Senior Salix | Profile | |
Graham Jackson | Senior Officer | Profile | |
Sam Will | Senior Vice President - Finance, Chief Accounting Officer, Controller | Profile | |
Thomas Vadaketh | Ex CFO | Profile | |
Kathleen Fitzpatrick | Senior Officer | Profile | |
Jiny MBA | Senior Medical | Profile | |
Donald Pearl | Senior Dermatologics | Profile | |
Steven Miller | Independent Director | Profile | |
Robert Spurr | President - Salix | Profile | |
Cees Heiman | Senior Canada | Profile |
About Bausch Health Management Performance
The success or failure of an entity such as Bausch Health Companies often depends on how effective the management is. Bausch Health management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bausch management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bausch management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.06) | (0.06) | |
Return On Capital Employed | 0.04 | 0.04 | |
Return On Assets | (0.02) | (0.02) | |
Return On Equity | 0.58 | 0.61 |
The data published in Bausch Health's official financial statements usually reflect Bausch Health's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bausch Health Companies. For example, before you start analyzing numbers published by Bausch accountants, it's critical to develop an understanding of what Bausch Health's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Bausch Health's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bausch Health's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bausch Health's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bausch Health Companies. Please utilize our Beneish M Score to check the likelihood of Bausch Health's management manipulating its earnings.
Bausch Health Workforce Analysis
Traditionally, organizations such as Bausch Health use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bausch Health within its industry.Bausch Health Manpower Efficiency
Return on Bausch Health Manpower
Revenue Per Employee | 432K | |
Revenue Per Executive | 230.4M | |
Net Loss Per Employee | 30.1K | |
Net Loss Per Executive | 16.1M | |
Working Capital Per Employee | 63.8K | |
Working Capital Per Executive | 34.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Bausch Health Companies information on this page should be used as a complementary analysis to other Bausch Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Bausch Stock analysis
When running Bausch Health's price analysis, check to measure Bausch Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bausch Health is operating at the current time. Most of Bausch Health's value examination focuses on studying past and present price action to predict the probability of Bausch Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bausch Health's price. Additionally, you may evaluate how the addition of Bausch Health to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Bausch Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.115 | Earnings Share (1.62) | Revenue Per Share 23.998 | Quarterly Revenue Growth 0.098 | Return On Assets 0.0382 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.